top of page

Latest News

Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe

Durham, North Carolina, October 6, 2023 — Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present at Bio Investor Forum October 16-18, 2023 in San Francisco, Calif. and Bio Europe November 6-8, 2023, in Munich, Germany. During the company’s presentations, President and Chief Executive Officer John Whelan will discuss progress in the development of the company’s inhaled antibody platform and drugs in development for respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza.


Inhalon Biopharma’s breakthrough platform for treating ARIs enables inhaled antibodies to trap viruses and other pathogens in airway mucus to block the infection from spreading within the lung, and to rapidly eliminate the pathogens through natural mucus clearance. Inhalon has demonstrated the efficacy of our technology in multiple in vivo infection models and has completed two Phase 1 studies demonstrating safety and favorable pharmacokinetics.


“Inhalon was founded on the idea that early, convenient, outpatient treatments for acute respiratory infections could reduce incidence of severe disease and its associated costs to patients and the health care system,” said John Whelan, president and chief executive officer, Inhalon Biopharma. “We are developing a pipeline of proprietary inhaled antibody treatments which could one day improve the outcomes for patients with acute respiratory infections and set a new standard of acute respiratory infection care.”


Inhalon Biopharma-developed therapeutics are designed to be self-administered by patients using a handheld portable nebulizer, making them easier to administer, store, and distribute compared to antibodies designed for intravenous delivery.

Bio Investor Forum Presentation Details

Date and Time: Wednesday, October 18, 2023, at 11:15 a.m. PT

Location: Hilton San Francisco Union Square, Franciscan D Room


Bio Europe Presentation Details

Date and Time: Monday, November 6, 2023, at 3:00 p.m. DST

Location: Messe München, San Sebastian Room


About Inhalon Biopharma

Inhalon Biopharma is a clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Life Science Angels, and JSR Life Sciences as well as several federal grants from the NIH and USAMRDC.



John Whelan



Gwen Gordon

bottom of page